CJC-1295 vs Tesamorelin

CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.

CJC-1295 (DAC-GRF) is a synthetic 30-amino-acid GHRH analog incorporating a Drug Affinity Complex (DAC) modification — trans-4-aminomethylcyclohexane carboxylic acid — that enables covalent binding to circulating albumin, dramatically extending the plasma half-life from minutes (as with native GHRH) to approximately 6–8 days and enabling once or twice-weekly dosing for sustained GH and IGF-1 elevation. The extended half-life allows CJC-1295 to act as a continuous GHRH-receptor agonist at pituitary somatotrophs rather than producing pulsatile stimulation, stimulating cumulative GH secretion and downstream IGF-1 production; this pharmacokinetic profile distinguishes it from short-acting GHRH analogs such as sermorelin and positions it for research in GH axis restoration. A Phase 1 dose-escalation RCT in healthy adults published in the Journal of Clinical Endocrinology and Metabolism (2006) demonstrated dose-dependent and sustained increases in mean GH and IGF-1 concentrations following single-dose administration, establishing the only indexed human pharmacokinetic and pharmacodynamic data for this compound; all other indexed literature consists of anti-doping detection methods. CJC-1295 has no FDA approval and no approved therapeutic indication in any jurisdiction; it is available only as a research compound and the clinical evidence base is limited to a single Phase 1 safety and PK study in healthy subjects, with no Phase 2 or Phase 3 data addressing efficacy for any specific indication. CJC-1295 and ipamorelin combination: CJC-1295 is most commonly studied in combination with ipamorelin, a selective GHRP (growth hormone-releasing peptide), because the two compounds act on complementary pathways to stimulate GH release. CJC-1295 activates the GHRH receptor at pituitary somatotrophs, providing a sustained permissive signal for GH secretion; ipamorelin activates the ghrelin receptor (GHS-R1a), producing a discrete GH pulse with high selectivity and without meaningfully elevating cortisol or prolactin. Research and clinical interest in the combination centers on the synergistic GH pulse amplitude achieved when both pathways are stimulated together — greater than either compound alone. The pharmacokinetic profiles are complementary: CJC-1295's extended half-life (6–8 days) provides a stable GHRH background, while ipamorelin's short half-life (approximately 2 hours) allows timed pulsatile stimulation. In clinical research contexts, CJC-1295 is typically administered subcutaneously one to two times weekly to maintain a sustained GH baseline, while ipamorelin is dosed more frequently — daily or multiple times per day — to generate GH pulses aligned with sleep or exercise. A triple-stack combining CJC-1295, ipamorelin, and sermorelin is referenced in some clinical contexts for additive GH axis stimulation, though evidence supporting the triple combination beyond individual compound data is limited. All dosing references are for research contexts only; no approved clinical protocols exist for any of these combinations. Subcutaneous vs intramuscular injection for CJC-1295: CJC-1295 is administered exclusively via subcutaneous injection in all published research — intramuscular injection is not used for this compound. Subcutaneous injection into abdominal fat or thigh tissue results in slower, more consistent absorption suitable for the depot-like pharmacokinetic profile that CJC-1295's DAC modification already provides. Rotation of injection sites is recommended to avoid lipohypertrophy at repeated injection locations. Injection technique, site preparation with an alcohol swab, and proper needle gauge selection (typically 27–31G for subcutaneous peptide injection) are standard considerations across all subcutaneous peptide administration contexts.

Tesamorelin stimulates pulsatile GH secretion from the anterior pituitary by binding GHRH receptors. Its stabilisation protects it from rapid enzymatic cleavage by dipeptidyl peptidase IV, extending the effective half-life compared to unmodified GHRH. Downstream effects on visceral adiposity are mediated through elevated IGF-1 and direct lipolytic signalling.

Tesamorelin (GHRH(1-44)-trans-3-hexenoic acid; Egrifta) is a synthetic 44-amino-acid analog of endogenous growth hormone-releasing hormone conjugated with a trans-3-hexenoic acid moiety to confer resistance to DPP-IV enzymatic degradation and extend its plasma stability, developed and approved as the first GHRH analog indicated for a metabolic complication of HIV antiretroviral therapy — specifically visceral adiposity from HIV-associated lipodystrophy. Tesamorelin activates GHRH receptors on pituitary somatotrophs to stimulate pulsatile GH secretion and downstream hepatic IGF-1 production; the resulting normalization of GH pulse amplitude in treated patients reduces visceral adipose tissue through lipolytic signaling in visceral fat depots, without the risk of direct supraphysiological GH administration. A pivotal Phase 3 randomized placebo-controlled trial in HIV-infected adults on antiretroviral therapy demonstrated significant and sustained reductions in visceral adipose tissue area by MRI imaging versus placebo, with a favorable safety profile in this immunocompromised population, providing the pivotal evidence for FDA approval in 2010. Tesamorelin (Egrifta, Theratechnologies) is FDA-approved and requires a prescription; it is indicated specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy and is not approved for general fat loss, body composition improvement, anti-aging, or GH deficiency applications outside the HIV-lipodystrophy indication. Tesamorelin dosage and where to get it: Tesamorelin (Egrifta) is administered as a once-daily subcutaneous injection of 2mg in its FDA-approved indication for HIV-associated lipodystrophy; this is the only dose and indication with established clinical evidence. In off-label research contexts examining body composition and GH axis support in non-HIV populations, tesamorelin has been studied at similar dose ranges, though no approved protocol exists for these applications. Where to find tesamorelin: as an FDA-approved prescription medication, tesamorelin is available through licensed pharmacies in the United States with a valid prescription. Compounding pharmacies may also prepare tesamorelin for off-label clinical use under physician supervision. Telehealth providers specializing in peptide therapy and hormone health sometimes offer tesamorelin consultations for eligible patients. PeptideBase maintains a directory of verified providers — including telehealth platforms — for those researching access to tesamorelin through supervised clinical channels.